JB Chemicals & Pharmaceuticals Limited

rs,

ironment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company

70%

istent track record across multiple businesses 5 Brands among top 300 brands, contributing over 70% of domestic formulations revenues 40+ Regulated/semi-regulated markets of presence through di

21%

Top 5 Global manufacturer of medicated/herbal lozenges representing a substantial opportunity 21% Growth in chronic therapies* in the domestic formulations business 2100+ Strong India field f

42%

cused segmentation 7 Multi-dosage formulation plants with key global approvals/ compliances **42% ROCE with strong cash position and consistent cash flow generation * CAGR over FY17-FY21 # Incl

27.4%

Mutual Fund Investments) 5 Revenue (INR cr) PAT (INR cr) EBITDA Margin (%) ROE (%) ROCE (%) 27.4% 18.6% 21.3% 1,643 1,775 2,043 15.4% 1,413 139 194 272 449 FY18 FY19 FY20 FY21 Finan

18.6%

Fund Investments) 5 Revenue (INR cr) PAT (INR cr) EBITDA Margin (%) ROE (%) ROCE (%) 27.4% 18.6% 21.3% 1,643 1,775 2,043 15.4% 1,413 139 194 272 449 FY18 FY19 FY20 FY21 Financial Ye

21.3%

nvestments) 5 Revenue (INR cr) PAT (INR cr) EBITDA Margin (%) ROE (%) ROCE (%) 27.4% 18.6% 21.3% 1,643 1,775 2,043 15.4% 1,413 139 194 272 449 FY18 FY19 FY20 FY21 Financial Year ends

15.4%

cr) PAT (INR cr) EBITDA Margin (%) ROE (%) ROCE (%) 27.4% 18.6% 21.3% 1,643 1,775 2,043 15.4% 1,413 139 194 272 449 FY18 FY19 FY20 FY21 Financial Year ends on 31st March 15% 10% FY

15%

2,043 15.4% 1,413 139 194 272 449 FY18 FY19 FY20 FY21 Financial Year ends on 31st March 15% 10% FY18 24% 13% FY19 42% 25% 29% 19% FY20 FY21 6 86 24 224 FY21 Business-wise Rev

10%

15.4% 1,413 139 194 272 449 FY18 FY19 FY20 FY21 Financial Year ends on 31st March 15% 10% FY18 24% 13% FY19 42% 25% 29% 19% FY20 FY21 6 86 24 224 FY21 Business-wise Revenue

24%

413 139 194 272 449 FY18 FY19 FY20 FY21 Financial Year ends on 31st March 15% 10% FY18 24% 13% FY19 42% 25% 29% 19% FY20 FY21 6 86 24 224 FY21 Business-wise Revenue (INR crore)

13%

139 194 272 449 FY18 FY19 FY20 FY21 Financial Year ends on 31st March 15% 10% FY18 24% 13% FY19 42% 25% 29% 19% FY20 FY21 6 86 24 224 FY21 Business-wise Revenue (INR crore) 63

“Going forward, we will maintain focus on driving topline growth, cost optimization and organizational efficiencies.”

Source

1

ISIN

1

Source

IQVIA Data, Dec-21. Covered market includes all JBCPL’s molecule segments 100% 80% 60% 40% 20% 0% Increasing Contribution from Chronic Therapies (MAT Dec data) 64% 60% 57% 54% 54% 36% 40% 43% 46% 46% MAT 17 MAT 18 MAT19 MAT 20 MAT 21 Chronic Therapy (%) Acute Therapy ( %) FY21 International Business Revenues INR 1,127 crore Intl Formulations* 72 % CMO* 20 % APIs* 8 % 817 224 86 9M FY22 International Business Revenues INR 896 crore Intl Formulations* 75 % CMO* 18% APIs* 7 % 668 165 63 * Contribution to international business * Contribution to international business International Formulations RUSSIA Prescription branded generics business built over three decades o o Well established brand equity, 80-strong sales force, pharmacy relationships SOUTH AFRICA o Well-entrenched in public and private markets o 30-strong sales force, retail pharmacy relationships, access to in-house/third-party products UNITED STATES o Generics business in niche products, delayed release OSD(Oral Solid Dosage) f

ISIN

is one of the INE572A01028), established in 1976, fastest growing pharmaceutical companies in India and a leading player in the hypertension segment. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has five brands among the top 300 brands in the country. finished formulations to over 30 countries including the USA. Besides supplying branded generic formulations to several countries, in the manufacturing of medicated lozenges. The company ranks among the top 5 manufacturers globally in medicated and herbal lozenges. It has seven state of the art manufacturing facilities in India including a dedicated manufacturing facility for medicated lozenges. The manufacturing facilities are certified by leading regulators across the world. is also a leader company exports The its it For more and Pharmaceuticals Limited, please visit www.jbcpl.com. Chemicals details J.B. on For further inform